Pear Therapeutics (NASDAQ: PEAR) presented real-world data on its prescription digital therapeutic, reSET, targeting alcohol use disorder (AUD) during the American Association of Addiction Psychiatry meeting (December 8-11, 2022). The study involved 548 patients and highlighted key outcomes: a 69.7% retention rate in treatment during the final four weeks and 59% achieving abstinence. These findings suggest reSET’s potential to engage patients and improve treatment outcomes for AUD, although the product awaits FDA marketing authorization for this specific indication.
Pear Therapeutics (Nasdaq: PEAR) reported a 24% revenue growth quarter-over-quarter, reaching $4.1 million for Q3 2022, a significant increase from $1.3 million in Q3 2021. The company cut operating expenses by 15% and plans to save approximately $10.7 million in 2023 due to a workforce reduction of 22%. Initiatives to expand patient access include new partnerships and market expansions. The company reaffirms its revenue guidance of $14-16 million for 2022 and projects $27-37 million for 2023.
Pear Therapeutics, Inc. (NASDAQ: PEAR), a leader in developing software-based medicines, announced participation in the virtual BTIG Digital Health Forum on November 21, with President and CEO Corey McCann set for a fireside chat at 10:00 a.m. ET. This forum is exclusive to BTIG clients. Pear Therapeutics focuses on prescription digital therapeutics (PDTs), boasting a robust pipeline including the first FDA-authorized PDT for substance use disorder, reSET®, and others aimed at improving health outcomes through innovative digital solutions.
Pear Therapeutics, Inc. (NASDAQ: PEAR) announced a retrospective analysis showing that its FDA-authorized prescription digital therapeutic, Somryst®, significantly reduces healthcare resource use and costs for patients with chronic insomnia. The analysis revealed an average per-patient savings of $8,202 over 24 months compared to traditional insomnia medications. Notable reductions in hospitalizations (55%) and emergency department services (59%) were recorded, emphasizing Somryst's potential clinical and economic benefits in treating chronic insomnia.
Pear Therapeutics (NASDAQ: PEAR) has been awarded funding by the Wisconsin Department of Health Services to provide residents with access to its FDA-authorized digital therapeutics, reSET® and reSET-O®, aimed at treating substance use and opioid use disorders. This initiative aligns with DHS's goal to enhance health support for individuals facing addiction. The state reported a significant increase in fentanyl-related overdose deaths, highlighting the urgent need for effective treatment options.
Pear Therapeutics, traded as PEAR on Nasdaq, announced its participation in the Credit Suisse 31st Annual Healthcare Conference on November 8 in Rancho Palos Verdes, California. Corey McCann, M.D., Ph.D., will represent the company in an analyst-led fireside chat at 3:15 p.m. Pacific Time. A live audio webcast will be accessible on Pear's website and available for 30 days after the event. Pear Therapeutics is a leader in developing software-based medicines, known as prescription digital therapeutics (PDTs), with groundbreaking FDA approvals in substance use and chronic insomnia treatments.
Pear Therapeutics, Inc. (NASDAQ: PEAR) will announce its third quarter 2022 financial results on November 14, 2022, after market close. An investor conference call is scheduled for 4:30 p.m. ET on the same day to discuss financial and business highlights. Participants can register for the call online, and a replay will be available within two hours post-call for 30 days. Pear Therapeutics specializes in software-based medicines known as prescription digital therapeutics (PDTs), aiming to improve patient outcomes and provide effective solutions for clinicians and payers.
Pear Therapeutics (NASDAQ: PEAR) has published a real-world observational analysis demonstrating the effectiveness of its FDA-authorized prescription digital therapeutic, reSET, for substance use disorder (SUD) across a diverse patient population. The study, published in The American Journal on Addictions, found that over 74% of patients were retained in treatment, with abstinence rates of 62% to 86% during the final weeks. The results support the potential of reSET to improve engagement and retention in treatment, addressing challenges faced by many patients early in their recovery journey.
Pear Therapeutics, Inc. (NASDAQ: PEAR) announced its participation in the LifeSci Partners HealthTech Symposium on September 20, 2022. CEO Corey McCann, M.D., Ph.D., will join a virtual fireside chat at 12:30 p.m. ET. Interested parties can access a live audio webcast of the event here, and a replay will be available on Pear's website for 30 days post-event.
Pear Therapeutics, Inc. (Nasdaq: PEAR) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference from September 12-14, 2022, in New York City. CEO Corey McCann will engage in a fireside chat on September 14 at 2:05 p.m. ET. Pear will also host one-on-one meetings with investors during the conference. A live audio webcast of the presentation can be accessed here and on Pear's website.